Trilo Therapeutics

Executive Summary

Trilo Therapeutics is a preclinical-stage biotechnology company pioneering a novel class of targeted cancer therapeutics called Trilomer® peptidomimetics. Based in San Diego, the company's platform leverages fully synthetic D-amino acid peptides designed to deliver potent chemotherapy drugs or radionuclides directly to tumors. This approach aims to overcome key limitations of traditional antibody-drug conjugates (ADCs) and peptide-drug conjugates by enabling rapid tumor penetration and systemic clearance, thereby reducing off-target toxicity. Despite being in early development, Trilo's technology has the potential to improve the therapeutic index of cytotoxic agents and expand the treatable patient population. The company is privately held and has not disclosed total funding or valuation, but its science addresses a significant unmet need in oncology. Key risks include the preclinical stage, lack of disclosed pipeline details, and the inherent challenges of translating novel drug formats into clinical candidates. However, if successful, the Trilomer platform could offer a differentiated approach to targeted cancer therapy.

Upcoming Catalysts (preview)

• TBDCompletion of IND-enabling studies30% success
• TBDAnnouncement of lead candidate selection50% success
• TBDPartnership or licensing deal for platform technology20% success